NitroMist
NitroMist (NDA 021780), the FDA-approved nitroglycerin lingual aerosol for angina, is returning to market under Vicapsys Life Sciences: the product, its history, and the relaunch.
vicapsys.comCrawled Nov 19, 2026
NitroMist (NDA 021780), the FDA-approved nitroglycerin lingual aerosol for angina, is returning to market under Vicapsys Life Sciences: the product, its history, and the relaunch.
The Vicapsys platform: Stateline wholesale distribution, the federal and tribal channel, Puerto Rico brand supply at DACO pricing, NitroMist and VICAPSYN.
VICAPSYN: cell replacement for type 1 diabetes designed to work without systemic immunosuppression, using CXCL12 immune-isolation technology licensed from Massachusetts General Hospital.
Press release, October 5, 2026: Housekeeping starts with branding: Vicapsys Life Sciences adopts a new corporate identity by FutureBrand
Press releases and announcements from Vicapsys Life Sciences, Inc. (OTC: VICP).
Press release, November 2, 2026: Vicapsys Life Sciences provides shareholder update on VICAPSYN: program advancing toward Phase 1 human clinical trial, vertically integrated with the Company's Indian Health Service strategy
Press release, September 25, 2026: Vicapsys Life Sciences announces Advisory Board following completion of Stateline merger
Press release, September 22, 2026: Vicapsys Life Sciences completes reverse merger with Stateline Distributors of Puerto Rico and signs definitive agreement to acquire NitroMist
Contact Vicapsys Life Sciences, Inc. and Stateline Distributors of Puerto Rico: media and investor inquiries, business development, and the San Juan operations address.
Vicapsys Life Sciences, Inc. (OTC: VICP): a public pharmaceutical platform company combining licensed wholesale drug distribution, federal contracting access, and owned FDA-approved products.